LJPC - La Jolla Pharmaceutical Company
6.30 +0.05 (0.80%)
After hours: 7:48PM EST
| Previous Close | 6.56 |
| Open | 6.55 |
| Bid | 6.30 x 1000 |
| Ask | 6.36 x 800 |
| Day's Range | 6.22 - 6.75 |
| 52 Week Range | 5.01 - 41.36 |
| Volume | 1,256,943 |
| Avg. Volume | 815,211 |
| Market Cap | 163.96M |
| Beta (3Y Monthly) | 3.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.92 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 39.83 |
- ACCESSWIRE•8 days ago
Biotech Companies to Watch
HENDERSON, NV / ACCESSWIRE / January 10, 2019 / Biotech has started 2019 off with a bang. Below are a few that you should be paying attention to. One that looks poised for a big year, Delcath Systems, ...
- Benzinga•8 days ago
HC Wainwright Slashes La Jolla Pharma Price Target, Estimates On Below-Expectation Guidance
La Jolla Pharmaceutical Company (NASDAQ: LJPC ) reported net 2018 sales of $10.1 million for the septic shock treatment Giapreza this week and announced 2019 sales guidance of $24 million to $28 million ...
- Motley Fool•10 days ago
Here's Why La Jolla Pharmaceutical Tumbled Today
The company provided preliminary operating results for 2018 and expectations for the year ahead.
- TheStreet.com•10 days ago
La Jolla Stock Plummets 44% After Disappointing Drug Sales Projections
La Jolla's share price fell to $5.64 by 2:34 pm, down from its close of $10.52 on Friday, after the company said it expects sales of low blood pressure drug Giapreza to hit $24 million-$28 million in 2019, roughly half of what analysts had projected. The pharmaceutical company's stock has been trending downward since late September, when it was trading at more than $22. La Jolla reported a 20% increase during the fourth quarter in sales of Giapreza, first launched in March, with sales of the drug, used to increase blood pressure in patients suffering from septic or distributive shock.
- MarketWatch•10 days ago
La Jolla Pharmaceutical's stock plummets to pace Nasdaq losers after downbeat drug guidance
Shares of La Jolla Pharmaceutical Co. plummeted 44% in midday trade Monday to pace all Nasdaq losers, after the company provided downbeat guidance on its key drug that treats dangerously low blood pressure in adults with septic or other disruptive shock. The company said its fourth-quarter sales of Giapreza, which was launched in March 2018, rose 20% from a year ago to $4.2 million, with 2018 sales expected to reach $10.1 million. The Giapreza sales estimates of the two analysts that provided estimates to FactSet ranged from $5.2 million to $6.9 million for the fourth quarter and $11.1 million to $12.8 million for 2018. For 2019, La Jolla Pharmaceuticals said it expects Giapreza sales to rise to $24 million to $28 million, while analyst estimates ranged from $44.3 million to $55.0 million. The stock, on track for the lowest close since September 2013, has now plummeted 68% over the past three months, while the S&P 500 has declined 11%.
- GlobeNewswire•10 days ago
La Jolla Pharmaceutical Company Highlights Recent Corporate Progress and Key Objectives
- Fourth-Quarter 2018 Net Sales of GIAPREZA Were Approximately $4.2 Million, Up 20% from the Third Quarter of 2018 - - Full-Year 2019 Net Sales Guidance for GIAPREZA of $24.
- GlobeNewswire•13 days ago
La Jolla Pharmaceutical Company to Present at the 37th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 04, 2019 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to.
- Insider Monkey•27 days ago
Hedge Funds Are Crazy About La Jolla Pharmaceutical Company (LJPC)
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Carl Icahn and George Soros think. Those hedge fund operators make billions of dollars each […]
- GlobeNewswire•2 months ago
Research Report Identifies Exelon, La Jolla Pharmaceutical, Kennedy-Wilson, Fluidigm, Telefonica SA, and Cognex with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Nov. 06, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of LJPC earnings conference call or presentation 24-Oct-18 8:30pm GMT
Q3 2018 La Jolla Pharmaceutical Co Earnings Call
- ACCESSWIRE•3 months ago
3 Healthcare Stocks To Watch On Thursday
CORAL GABLES, FL / ACCESSWIRE / October 25,2018 / Healthcare stocks have helped to boost the US equity markets today. The Select Sector SPDR Healthcare ETF (XLV) has had a strong recovery on Thursday and the broader markets are also surging. The healthcare industry has seen a shakeup recently as new technology innovation and further research on new drugs pushes industry margins.
- Zacks•3 months ago
La Jolla Pharmaceutical (LJPC) Reports Q3 Loss, Tops Revenue Estimates
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 3.98% and 2.82%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
La Jolla Pharmaceutical: 3Q Earnings Snapshot
The San Diego-based company said it had a loss of $1.93 per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss ...
- GlobeNewswire•3 months ago
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2018
SAN DIEGO, Oct. 24, 2018 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to.
- Benzinga•3 months ago
The Daily Biotech Pulse: Illumina's Strong Q3, Celgene's Positive Cancer Drug Trial, Proteostasis Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 23) Amarin Corporation plc (NASDAQ: AMRN ) Imprimis Pharmaceuticals ...
- Simply Wall St.•3 months ago
Why You Need To Look At This Factor Before Buying La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Anyone researching La Jolla Pharmaceutical Company (NASDAQ:LJPC) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and Read More...
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of LJPC earnings conference call or presentation 8-Aug-18 8:30pm GMT
Q2 2018 La Jolla Pharmaceutical Co Earnings Call
- Motley Fool•5 months ago
Why La Jolla Pharmaceutical Is Tumbling Today
Shares drop off after the company reports second-quarter results that left investors wanting more.
- Zacks•5 months ago
La Jolla Pharmaceutical (LJPC) Reports Q2 Loss, Misses Revenue Estimates
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -5.76% and -35.64%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•5 months ago
La Jolla Pharmaceutical: 2Q Earnings Snapshot
The San Diego-based company said it had a loss of $2.02 per share. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for ...
- ACCESSWIRE•5 months ago
La Jolla Pharmaceutical Company to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / La Jolla Pharmaceutical Company (NASDAQ: LJPC ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30:00 ...
